• Vertex Pharma inks another R&D alliance to expand its gene-editing ambitions

    25 days ago - By MedCity News

    Vertex Pharmaceuticals is collaborating with Obsidian Therapeutics to develop up to five new gene editing therapies. Obsidian's technology precisely controls protein expression, a capability the partners plan to apply to several undisclosed serious diseases.
    Read more ...